%0 Journal Article
%T SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023.
%A Carreño JM
%A Wagner AL
%A Monahan B
%A Singh G
%A Floda D
%A Gonzalez-Reiche AS
%A Tcheou J
%A Raskin A
%A Bielak D
%A Morris S
%A Fried M
%A Yellin T
%A Sullivan L
%A  
%A Sordillo EM
%A Gordon A
%A van Bakel H
%A Simon V
%A Krammer F
%J Nat Commun
%V 15
%N 1
%D 2024 Jul 11
%M 38992013
%F 17.694
%R 10.1038/s41467-024-50052-2
%X Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.